Biotech | October 01, 2021
Jubilant concludes pre-IND meeting of JB1-802 with U.S. FDA
The company plans to submit the IND application by the end of 2021
The company plans to submit the IND application by the end of 2021
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
A team of experts at Fortis Gurugram conducted 3-dimensional mapping with the help of the new system Carto version 7 to precisely map the source of the arrhythmia. It was detected that the arrhythmia was coming from the conduction system i.e. body’s natural wiring.
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Subscribe To Our Newsletter & Stay Updated
